Unapproved Depression Drug Remains Available In US In Supplements To Treat Opioid Addiction
Executive Summary
CSPI says FDA has warned companies about tianeptine, which stimulates opioid receptors and may trigger addiction and withdrawal symptoms. But “tianeptine products continue to be widely available in Alabama and online.”
You may also be interested in...
Opioid Abuse Treatment Claims Prompt FDA Warnings To Two Kratom Marketers
As in previous warnings to kratom supplement marketers linked to opioid addiction treatment claims, FDA tells Cali Botanicals and Kratom NC that HHS in 2017 found opioid abuse was nationwide public health emergency and FDA is targeting products that without approval claim to diagnose, mitigate, prevent, treat or cure opioid addiction. Contract manufacturer Somlabs' GMP problems also were identified in FDA's latest warning letters.
Opioid Treatment Claims Linked To Depression Drug Found In Supplements
FDA warns MA Labs and Jack B Goods about online claims that their tianeptine-containing products treat opioid use disorder, pain and anxiety and other violative and unproven claims. CDC reports a jump in poison control center reports on tianeptine, which is approved outside the US to treat depression.
DEA Proposal To Schedule Kratom Stirs Wave Of Opposition
AHPA and the American Botanical Council are among the opponents of DEA's proposal to schedule the active materials in kratom while NPA supports it, saying kratom products and raw ingredients have not met "the strict standards products and new ingredients must adhere to in order to be marketed to the public."